A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric

Medicine & Life Sciences

1. cemiplimab 100%
2. Pediatrics 31%
3. Central Nervous System Neoplasms 30%
4. Safety 28%
5. Pharmacokinetics 18%
6. Radiotherapy 16%